Biorasi’s CEO, Chris O’Brien, welcomes Karen Petrou and David Brint for an in-depth discussion on BioBonds and how they can jumpstart funding in clinical research for rare disease and other disorders.

https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/episode-18-karen-petrou-and-david-brint-biobonds